Theriva Biologics, Inc. (SFY.F)

0.3560 -0.0140 (-3.78%) At close: 08:20AM CEST

Theriva Biologics, Inc.

9605 Medical Center Drive
Suite 270
Rockville, MD 20850
United States
301 417 4364
https://therivabio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 22

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Steven A. Shallcross CPA	CEO, CFO, Treasurer, Corporate Secretary & Director	920.98k	N/A	1961
Dr. Vince Wacher Ph.D.	Head of Product & Corporate Development	N/A	N/A	N/A
Dr. Michael Kaleko M.D., Ph.D.	Senior Vice President of Research & Development	N/A	N/A	N/A
Dr. Ramon Alemany Ph.D.	Senior VP of Discovery & Chairman of Scientific Advisory Board	N/A	N/A	N/A
Ms. Lara M. Guzman	Senior Director of Project Operations	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d'Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.

Corporate governance

Theriva Biologics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.